Department of Adult Nursing, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
J Gastroenterol. 2013 Sep;48(9):1006-15. doi: 10.1007/s00535-012-0721-x. Epub 2012 Dec 4.
Thirty to forty-five percent of ulcerative colitis (UC) patients show non-adherence to aminosalicylates, and non-adherence has been reported to increase the risk of clinical relapse. Because Japan differs from Western countries in terms of health care and drugs administered, adherence to aminosalicylates in Japan may differ from that elsewhere. Therefore, we examined aminosalicylate adherence and its relationship to the risk of clinical relapse of UC in Japan.
A 1-year, prospective cohort study was conducted in 104 outpatients with UC in remission who had taken aminosalicylates >6 months. Aminosalicylate adherence was evaluated using data from a self-administered questionnaire and medical records. Non-adherence was defined as taking <80 % of the prescribed dose of aminosalicylates. The primary outcome was the record of clinical relapse in medical charts.
Twenty-nine patients (27.9 %) were evaluated as showing non-adherence. Among all subjects, 24 patients (23.1 %) relapsed. The non-adherence group had a higher rate of 1-year relapse than did the adherence group (41.3 vs. 16.0 %). Multiple Cox regression analysis showed that non-adherence increased the risk of clinical relapse 2.3-fold (hazard ratio 2.3, 95 % confidence interval 1.004-5.24, p = 0.04).
Although the adherence rate in this study was slightly higher than that in previous studies, Japanese patients with UC who were not adherent to their medications had a twofold greater risk of relapse than those who were. These results indicate the importance of early identification of patients with non-adherence. A program to support medication taking behavior is needed to prevent UC relapse.
30%至 45%的溃疡性结肠炎(UC)患者对氨基水杨酸制剂的依从性较差,且已有报道称不依从会增加临床复发的风险。由于日本在医疗保健和药物管理方面与西方国家不同,因此日本患者对氨基水杨酸制剂的依从性可能与其他国家不同。因此,我们研究了日本溃疡性结肠炎患者的氨基水杨酸制剂依从性及其与临床复发风险的关系。
对 104 例缓解期服用氨基水杨酸制剂>6 个月的溃疡性结肠炎门诊患者进行了为期 1 年的前瞻性队列研究。通过自填问卷和病历数据评估氨基水杨酸制剂的依从性。不依从定义为服用的氨基水杨酸制剂剂量<规定剂量的 80%。主要结局是病历中记录的临床复发情况。
29 例(27.9%)患者被评估为不依从。在所有受试者中,24 例(23.1%)复发。不依从组的 1 年复发率高于依从组(41.3%比 16.0%)。多因素 Cox 回归分析显示,不依从使临床复发的风险增加了 2.3 倍(危险比 2.3,95%置信区间 1.004-5.24,p=0.04)。
尽管本研究的依从率略高于以往研究,但与依从治疗的患者相比,不依从治疗的日本 UC 患者复发风险增加了两倍。这些结果表明,早期识别不依从的患者非常重要。需要制定支持药物治疗行为的方案来预防 UC 复发。